Description: Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina. The company was founded in 2003 and is headquartered in Montréal, Canada.
Home Page: www.milestonepharma.com
MIST Technical Analysis
1111 Dr. Frederik-Philips Boulevard
Montreal,
QC
H4M 2X6
Canada
Phone:
514 336 0444
Officers
| Name | Title |
|---|---|
| Mr. Joseph G. Oliveto M.B.A. | CEO, Pres & Director |
| Mr. Amit Hasija | CFO & Exec. VP of Corp. Devel. |
| Dr. Philippe Douville M.B.A., Ph.D. | Founder, Strategic Advisor & Member of Scientific Advisory Board |
| Mr. Jeff Nelson | Chief Operating Officer |
| Mr. Roshan Girglani | VP of Marketing |
| Ms. Kimberly Sheehan | VP of HR |
| Dr. Philip T. Sager FACC, FAHA, FHRS, M.D. | Chief Medical Advisor & Member of the Scientific Advisory Board |
| Dr. Guy Rousseau | SVP of Regulatory Affairs and Quality Management |
| Mr. Lorenz Muller | Chief Commercial Officer |
| Dr. David B. Bharucha FACC, M.D., Ph.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7242 |
| Price-to-Sales TTM: | 86.8579 |
| IPO Date: | 2019-05-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 29 |